These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 28701219

  • 1. Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma.
    Gkika E, Schultheiss M, Bettinger D, Maruschke L, Neeff HP, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu AL, Brunner TB.
    Radiat Oncol; 2017 Jul 12; 12(1):116. PubMed ID: 28701219
    [Abstract] [Full Text] [Related]

  • 2. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
    Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C, Navarria P, Fogliata A, Tomatis S, D'Agostino G, Iftode C, Mancosu P, Ceriani R, Torzilli G.
    J Cancer Res Clin Oncol; 2015 Jul 12; 141(7):1301-9. PubMed ID: 25644863
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Toxicity of Stereotactic Body Radiotherapy for Early to Advanced Stage Hepatocellular Carcinoma - Initial Experience From an Australian Liver Cancer Service.
    Liu HY, Lee Y, McLean K, Leggett D, Hodgkinson P, Fawcett J, Mott R, Stuart K, Pryor D.
    Clin Oncol (R Coll Radiol); 2020 Oct 12; 32(10):e194-e202. PubMed ID: 32345457
    [Abstract] [Full Text] [Related]

  • 4. Stereotactic body radiotherapy for primary hepatocellular carcinoma.
    Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e447-53. PubMed ID: 21645977
    [Abstract] [Full Text] [Related]

  • 5. Stereotactic body radiation therapy for centrally located hepatocellular carcinoma: outcomes and toxicities.
    Lazarev S, Hardy-Abeloos C, Factor O, Rosenzweig K, Buckstein M.
    J Cancer Res Clin Oncol; 2018 Oct 15; 144(10):2077-2083. PubMed ID: 30088143
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients.
    Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda E.
    Acta Oncol; 2014 Mar 15; 53(3):399-404. PubMed ID: 23962244
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma.
    Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA.
    Clin Transl Oncol; 2010 Mar 15; 12(3):218-25. PubMed ID: 20231127
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system.
    Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, Kunieda E.
    Int J Radiat Oncol Biol Phys; 2013 Mar 15; 85(4):1006-11. PubMed ID: 23102838
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma.
    Jang WI, Kim MS, Bae SH, Cho CK, Yoo HJ, Seo YS, Kang JK, Kim SY, Lee DH, Han CJ, Kim J, Park SC, Kim SB, Cho EH, Kim YH.
    Radiat Oncol; 2013 Oct 27; 8():250. PubMed ID: 24160944
    [Abstract] [Full Text] [Related]

  • 15. Stereotactic body radiotherapy in the management of hepatocellular carcinoma: An Australian multi-institutional patterns of practice review.
    Liu HY, Lee YD, Sridharan S, Choong ES, Le H, Wang W, Khor R, Chu J, Oar A, Mott R, Smart J, Jenkins T, Anderson N, Cross S, Loo KF, Wigg A, Stuart K, Pryor D.
    J Med Imaging Radiat Oncol; 2021 Jun 27; 65(3):365-373. PubMed ID: 33890425
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Esophageal dose tolerance to hypofractionated stereotactic body radiation therapy: risk factors for late toxicity.
    Stephans KL, Djemil T, Diaconu C, Reddy CA, Xia P, Woody NM, Greskovich J, Makkar V, Videtic GM.
    Int J Radiat Oncol Biol Phys; 2014 Sep 01; 90(1):197-202. PubMed ID: 25015204
    [Abstract] [Full Text] [Related]

  • 18. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.
    Sanuki N, Takeda A, Mizuno T, Oku Y, Eriguchi T, Iwabuchi S, Kunieda E.
    AJR Am J Roentgenol; 2013 Dec 01; 201(6):W812-20. PubMed ID: 24261388
    [Abstract] [Full Text] [Related]

  • 19. Safety and Efficacy of Accelerated Hypofractionation and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Varying Degrees of Hepatic Impairment.
    Nabavizadeh N, Waller JG, Fain R, Chen Y, Degnin CR, Elliott DA, Mullins BT, Patel IA, Dyer BA, Fakhoury K, Naugler WE, Farsad K, Tanyi JA, Fuss M, Thomas CR, Hung AY.
    Int J Radiat Oncol Biol Phys; 2018 Mar 01; 100(3):577-585. PubMed ID: 29413273
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.